Chapter
The Challenges of Scaling Synthetic Biology
1:10:42 - 1:13:32 (02:49)
Synthetic biology company, Josh Hoffman and his team set out to create a factory using biology, but discovered that although the science worked in the lab, scaling it up presented a whole new set of challenges.
Clips
Zymurgen has been acquired by Ginkgo Bioworks for $300 million, following their IPO and raising a total of $1.5 billion since 2013.
1:10:42 - 1:11:21 (00:39)
Biotech
Summary
Zymurgen has been acquired by Ginkgo Bioworks for $300 million, following their IPO and raising a total of $1.5 billion since 2013. This acquisition highlights the increase in market competition and money flow in the biotech industry.
ChapterThe Challenges of Scaling Synthetic Biology
EpisodeE89: GDP growth negative in Q2, $SHOP layoffs, Alzheimer's fraud, Ginkgo acquires Zymergen & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
Josh Hoffman aimed to revolutionize manufacturing using synthetic biology to reduce costs and improve the time scale, but the reality of scaling up proved more challenging than anticipated.
1:11:21 - 1:13:32 (02:10)
Synthetic Biology
Summary
Josh Hoffman aimed to revolutionize manufacturing using synthetic biology to reduce costs and improve the time scale, but the reality of scaling up proved more challenging than anticipated.